Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The results suggest that the up-regulation of TMPRSS2 gene and the down-regulation of KLK11 gene in advanced and more aggressive tumors may open the feasibility of being used as biomarkers distinguishing the tumor aggressiveness as well as novel prognostic indicators for PCa.
|
19242826 |
2010 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In TMPRSS2 rearranged cases, the largest (index) tumor was rearranged 83% of the time.
|
17804708 |
2007 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Importantly, we also demonstrated that sGC inhibitor treatment repressed tumor growth in TMPRSS2-ERG-positive PCa xenograft models and can act in synergy with a potent AR antagonist, enzalutamide.
|
30718921 |
2019 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The complete absence of ERG-positive tumor areas in 6q15-deleted tumor foci further suggest that the functional consequences of 6q15 deletions may prevent the development of TMPRSS2:ERG fusions.
|
26684029 |
2016 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
RNA from radical prostatectomy tumour specimens was analysed using cDNA-mediated, annealing, selection, extension and ligation (DASL) to determine mRNAs associated with TMPRSS2-ERG T1/E4 fusion and prognostic of biochemical recurrence.
|
20068566 |
2010 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Tumor ERG protein expression (a <i>TMPRSS2:ERG</i> marker) was immunohistochemically assessed.
|
29167279 |
2018 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Unlike previous animal studies performed on PCa tumors lacking TMPRSS2:ETS, EB1089 (seocalcitol) (a less calcemic analog of 1,25D) did not inhibit the growth of TMPRSS2:ETS containing VCaP tumors in vivo, suggesting that the presence of TMPRSS2:ETS may limit the growth inhibitory actions of VDR.
|
24926821 |
2014 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In patients without prior A/E, blood and tumor TMPRSS2-ERG independently predicted lower PSA-PFS (HR 3.3, 95% CI 1.4-7.9 and HR 1.8, 95% CI 1.02-3.3, respectively) to taxanes.
|
30807643 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The deletion as cause of TMPRSS2:ERG fusion is associated with clinical features for prostate cancer progression compared with tumors that lack the TMPRSS2:ERG rearrangement.
|
16951139 |
2006 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The TMPRSS2-ERG gene rearrangement status of patient samples was determined by transformation of the exon array and RNA seq expression data to robust z-scores followed by the application of a threshold>3 to define a positive TMPRSS2-ERG gene fusion event in a tumour sample.
|
26575822 |
2015 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
First, PTEN deletion without TMPRSS2/ERG rearrangement was enriched in pT3/4 tumors (70% versus 48%) and tumors with Gleason grades of 8 to 9 (60% versus 17%) compared with the entire cohort.
|
26752304 |
2016 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Lastly, we found that the ability of TMPRSS2 to promote prostate cancer tumor growth and metastasis was associated with increased matriptase activation and enhanced degradation of extracellular matrix nidogen-1 and laminin β1 in tumor xenografts.
|
26018085 |
2015 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Using a sequencing-based approach, our work uncovers significant global epigenetic alterations in TMPRSS2-ERG gene fusion-negative tumors and provides a mechanistic explanation for the tumor formation process.
|
22930729 |
2012 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Cancer progression is driven by genome instability incurred rearrangements such as transmembrane protease, serine 2 (TMPRSS2)/v-ets erythroblastosis virus E26 oncogene (ERG) that could possibly turn some of the tumor suppressor micro-RNAs into pro-oncogenic ones.
|
28050800 |
2017 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
For example, genomic abnormalities involving the TMPRSS2-ETS and PTEN loci and the resulting signalling effects suggest the importance of genomic instability as a crucial factor in the emergence of this neoplasm.
|
18166163 |
2008 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
No difference in the frequency of TMPRSS2 gene alterations was found between Gleason 6 and 7 tumors.
|
20736744 |
2010 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We further conducted a systematic review and meta-analysis of TMPRSS2:ERG fusions in relation to race, Gleason score, and tumor stage, combining results from Ghana with 40 additional studies.
|
28633309 |
2017 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this study, we analyzed the status of <i>TMPRSS2-ERG</i> fusion genes and interstitial genes in tumors from a large cohort of men treated surgically for prostate cancer, associating alterations with biochemical progression.
|
29127096 |
2017 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Obesity and Prostate Cancer Risk According to Tumor TMPRSS2:ERG Gene Fusion Status.
|
25852077 |
2015 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In this study, we examined a series of adjacent G3 and Gleason pattern 4 (G4) tumors in radical prostatectomy specimens and found that all were concordant for the TMPRSS2:ERG gene fusion.
|
23204237 |
2013 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Here we report a frequency of 13% for TMPRSS2-ERG in tumors from Black South Africans.
|
31090091 |
2019 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We find that prostate cancer specimens containing the TMPRSS2-ERG rearrangement are significantly enriched for loss of the tumor suppressor PTEN.
|
19396168 |
2009 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Analysis of whole blood mRNA for T1:E4 translocation in TMPRSS2:ERG was consistent with that in the tumour in 8/9 evaluable cases (one was concordantly positive, seven were concordantly negative), SPINK1 results were concordant in 9/10 cases (two were concordantly positive, seven were concordantly negative [P = 0.047 for the predictive value]).
|
22313860 |
2012 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
A combination of high preoperative serum PSA and high expression of TMPRSS2-ERG could be promising in distinguishing those tumors that are aggressive and life-threatening.
|
27630329 |
2016 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Using confocal microscopy to identify cell-to-cell relationships in situ, we studied the most common gene rearrangement in prostate cancer (TMPRSS2 and ERG) and the tumor suppressor CHD1 in 56 patients who underwent radical prostatectomy.
|
25175909 |
2014 |